It suggested ICI therapy may be effective and promote a better prognosis for cervical cancer with high expression of FANCE. Blockade of PD-1 and PD-L1 immune checkpoints led to better outcomes in high-grade serous ovarian cancer and recurrent or metastatic endometrial cancer (Post et al., 2020; Wan et al., 2021). This evidence concerns the gene FANCE and ovarian serous adenocarcinoma.